|
|
|
Insider
Information: |
Berkman Charles S |
Relationship: |
Chief Legal Officer |
City: |
San Diego |
State: |
CA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
2 |
|
Direct
Shares |
316,442 |
|
Indirect Shares
|
0 |
|
|
Direct
Value |
$3,222,233 |
|
|
Indirect Value
|
$0 |
|
|
Total
Shares |
316,442 |
|
|
Total
Value |
$3,222,233 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
3
|
Stock
price went up :
|
0
|
1
|
Stock
price went down : |
0
|
2
|
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
Percentage
Gain/Loss : |
0.0%
|
-12.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Ligand Pharmaceuticals Inc |
LGND |
Former Executive Officer |
2022-11-01 |
23,825 |
|
0 |
Premium* |
|
OmniAb, Inc |
OABI |
Chief Legal Officer |
2024-04-08 |
292,617 |
2022-11-01 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
94 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 2 of 4
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
LGND |
Ligand Pharmaceuticals In... |
VP, Gen. Counsel & Secretary |
|
2014-02-12 |
4 |
A |
$0.00 |
$0 |
D/D |
2,500 |
29,645 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
VP, Gen. Counsel & Secretary |
|
2014-02-13 |
4 |
OE |
$14.47 |
$28,940 |
D/D |
2,000 |
31,645 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
VP, Gen. Counsel & Secretary |
|
2014-05-27 |
4 |
OE |
$9.96 |
$47,007 |
D/D |
2,499 |
27,464 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
VP, Gen. Counsel & Secretary |
|
2014-05-27 |
4 |
S |
$66.89 |
$479,434 |
D/D |
(7,166) |
26,978 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
VP, Gen. Counsel & Secretary |
|
2014-06-30 |
4 |
B |
$43.79 |
$14,408 |
D/D |
329 |
27,307 |
2.74 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
VP, Gen. Counsel & Secretary |
|
2014-12-31 |
4 |
B |
$45.23 |
$5,699 |
D/D |
126 |
27,433 |
2.74 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
VP, Gen. Counsel & Secretary |
|
2015-02-10 |
4 |
A |
$0.00 |
$0 |
D/D |
4,556 |
31,989 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
VP, Gen. Counsel & Secretary |
|
2015-03-16 |
4 |
OE |
$14.47 |
$106,939 |
D/D |
5,264 |
30,119 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
VP, Gen. Counsel & Secretary |
|
2015-03-16 |
4 |
S |
$74.51 |
$839,649 |
D/D |
(11,264) |
25,989 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
VP, Gen. Counsel & Secretary |
|
2015-06-30 |
4 |
A |
$45.67 |
$21,237 |
D/D |
465 |
26,454 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
VP, Gen. Counsel & Secretary |
|
2015-07-10 |
4 |
AS |
$98.15 |
$1,394,610 |
D/D |
(14,067) |
26,454 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
VP, Gen. Counsel & Secretary |
|
2015-07-10 |
4 |
OE |
$10.05 |
$178,687 |
D/D |
14,067 |
40,521 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
VP, Gen. Counsel & Secretary |
|
2015-07-13 |
4 |
OE |
$53.10 |
$53,100 |
D/D |
1,000 |
27,454 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
VP, Gen. Counsel & Secretary |
|
2016-02-11 |
4 |
A |
$0.00 |
$0 |
D/D |
2,193 |
29,647 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
VP, Gen. Counsel & Secretary |
|
2016-08-05 |
4 |
S |
$123.16 |
$2,717,772 |
D/D |
(22,067) |
29,647 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
VP, Gen. Counsel & Secretary |
|
2016-08-05 |
4 |
OE |
$21.92 |
$1,661,857 |
D/D |
30,347 |
37,927 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
VP, Gen. Counsel & Secretary |
|
2017-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
4,878 |
42,805 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
VP, Gen. Counsel & Secretary |
|
2017-06-30 |
4 |
A |
$87.13 |
$21,171 |
D/D |
243 |
43,048 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
VP, Gen. Counsel & Secretary |
|
2017-08-09 |
4 |
S |
$126.96 |
$2,364,671 |
D/D |
(18,625) |
24,423 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
VP, Gen. Counsel & Secretary |
|
2017-12-28 |
4 |
D |
$138.66 |
$162,926 |
D/D |
(1,175) |
26,095 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
VP, Gen. Counsel & Secretary |
|
2017-12-28 |
4 |
A |
$0.00 |
$0 |
D/D |
2,847 |
27,270 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
SVP, Gen. Counsel & Secretary |
|
2018-02-15 |
4 |
D |
$157.18 |
$162,838 |
D/D |
(1,036) |
25,059 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
SVP, Gen. Counsel & Secretary |
|
2018-03-02 |
4 |
A |
$0.00 |
$0 |
D/D |
1,780 |
26,839 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
SVP, Gen. Counsel & Secretary |
|
2018-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
1,136 |
27,975 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
SVP, Gen. Counsel & Secretary |
|
2018-03-06 |
4 |
D |
$165.87 |
$65,021 |
D/D |
(392) |
27,583 |
0 |
- |
|
94 Records found
|
|
Page 2 of 4 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|